A new drug trastuzumab for advanced breast cancer

How to treat HER2+ Breast Cancer in 2024 with Dr. Harold BursteinПодробнее

Special Session: New Drug Approvals for Metastatic Breast CancerПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

Dr. Ian Krop | San Antonio Breast Cancer Symposium 2022 | General SessionПодробнее

TUKYSA® (tucatinib) tablets Mechanism of Action VideoПодробнее

Highlights of the 2023 San Antonio Breast Cancer Symposium With Jason Mouabbi, MDПодробнее

How Are Antibody Drug Conjugates Used to Treat Breast Cancer? All You Need to KnowПодробнее

Q6 - New Developments in Drug TreatmentПодробнее

HER2-low status as a therapeutic target in advanced breast cancerПодробнее

Updates in Her2 +ve target therapy in advanced breast cancerПодробнее

Tucatinib With Capecitabine and Trastuzumab in Advanced HER2-Positive Breast CancerПодробнее

Updates in Her2 +ve target therapy in advanced breast cancerПодробнее

What is Metastatic or Advanced Breast Cancer? from Europa Donna MBC Advocacy Webinar 2022Подробнее

2021 West Oncology | Breast Cancer | Update on Brain MetastasesПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

New breast cancer drug delivers unprecedented levels of survival, stopping tumor growthПодробнее

Expanding options for HER2 advanced breast cancer: Taking trial data to the clinicПодробнее

New developments in the treatment of HER2 positive breast cancerПодробнее